We included MYC in the protocol because BMI1 was originally identified as an oncogene that cooperates with MYC in lymphoma production in mice [13], MYC is commonly amplified in human breast cancer, and several groups have reported that MYC is required for HMEC transformation. Here, BMI1 is linked to breast cancer.